Post mortem sampling of the brain and other tissues in neurodegenerative disease

The importance of the autopsy in neurodegenerative disease is often not appreciated. Yet clinical diagnosis of neurodegenerative disease is relatively inaccurate, many neurodegenerative diseases are inherited or are associated with specific genetic risk factors, and several non‐transmissible neurodegenerative diseases may be confused clinically with prion diseases. In all these cases, the autopsy is the only practical way in which brain tissue can be obtained for diagnosis. The pathologist should ensure that consent by the next‐of‐kin to post mortem examination is based on clear information as to the nature, scope and limitations of the autopsy, and that any constraints on retaining brain and other tissues are documented. The autopsy should be preceded by a careful review of the clinical notes and ante mortem studies, and consideration of the possible and likely pathological processes. This may suggest the need to retain fixed or frozen samples of cerebrospinal fluid, skeletal muscle, peripheral nerve and other tissues in addition to brain and spinal cord. Ideally, the brain should be fixed intact for 2–3 weeks before it is sliced and blocks are taken. If the period of fixation is limited to a few days only, it is best to slice the brain whilst it is fresh and to allow the diagnostically relevant slices to fix flat; after about 3 days the fixed slices can be sliced further, examined macroscopically and sampled. Even if consent is limited to the retention of only a few tissue samples for histology, a reasonably confident diagnosis can still usually be made, provided that the sampling is careful and systematic. The selection of blocks or brain and spinal cord for histology should be based on internationally accepted guidelines for the pathological diagnosis of different types of neurodegenerative disease, where such guidelines are available. Illustrations are provided to indicate which regions of the brain are critical to establishing a diagnosis in the main categories of neurodegenerative disease. When difficulties arise in the pathological diagnosis of neurodegenerative disease, inadequate post mortem sampling or rapid processing of poorly fixed brain tissue is usually to blame.

[1]  D. Dickson,et al.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank , 2003, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[3]  A. Gray,et al.  Estimating the relationship between disease progression and cost of care in dementia , 2002, British Journal of Psychiatry.

[4]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[5]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[6]  M Knapp,et al.  Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding , 2001, International journal of geriatric psychiatry.

[7]  K. Fischbeck Polyglutamine expansion neurodegenerative disease , 2001, Brain Research Bulletin.

[8]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[9]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[10]  R A Crowther,et al.  From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[11]  N P Quinn,et al.  What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[12]  J. Growdon,et al.  Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[13]  I Litvan,et al.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias , 1999, Neurology.

[14]  Linda Teri,et al.  Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series , 1999, Journal of the American Geriatrics Society.

[15]  P. Hobson,et al.  Accuracy of diagnosis in patients with presumed Parkinson's disease. , 1999, Age and ageing.

[16]  J. Hardy,et al.  Genetic classification of primary neurodegenerative disease. , 1998, Science.

[17]  James Lowe,et al.  Establishing a Pathological Diagnosis in Degenerative Dementias , 1998, Brain pathology.

[18]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[19]  J. Ironside Oppenheimer's Diagnostic Neuropathology: A Practical Manual , 1997 .

[20]  J. Bell,et al.  The ‘high‐risk’ neuropathological autopsy in AIDS and Creutzfeldt‐Jakob disease: principles and practice , 1996, Neuropathology and applied neurobiology.

[21]  D. Perl Oppenheimer's Diagnostic Neuropathology: A Practical Manual , 1996 .

[22]  W. Schlote,et al.  [Consensus report: tissue handling in suspected Creutzfeldt-Jakob disease and other spongiform encephalopathies (prion diseases) in the human. European Union Biomed-1 Concerted Action]. , 1996, Der Pathologe.

[23]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[24]  W. Schlote,et al.  Tissue Handling in Suspected Creutzfeldt‐Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases) , 1995, Brain pathology.

[25]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[26]  S. Love,et al.  Demonstration of mitochondrial ribosomal RNA in frozen and paraffin–embedded sections of skeletal muscle by in situ hybridization , 1994, Neuropathology and applied neurobiology.

[27]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[28]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[29]  S. Love,et al.  Qualitative and quantitative morphology of human sural nerve at different ages. , 1985, Brain : a journal of neurology.

[30]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[31]  R. Beesley,et al.  A Simple Method for Preparing Serial Blocks of Tissue , 1956, Journal of clinical pathology.

[32]  G. Tremblay Neuropathology , 1935, Neurology.

[33]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[34]  R. Weller,et al.  Autopsy investigation of disorders of skeletal muscle and peripheral nerves. , 2001, Current topics in pathology. Ergebnisse der Pathologie.

[35]  J. Lowe The pathological diagnosis of neurodegenerative diseases causing dementia. , 2001, Current topics in pathology. Ergebnisse der Pathologie.

[36]  J. Ironside,et al.  Investigation of prion diseases. , 2001, Current topics in pathology. Ergebnisse der Pathologie.

[37]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .